Month: September 2026

TR-1: Standard form for notification of major holdings

1. Issuer Details
ISIN
GB0009067447
Issuer Name
MOTHERCARE PLC.
UK or Non-UK Issuer
UK
2. Reason for Notification
An acquisition or disposal of voting rights
3. Details of person subject to the notification obligation
Name
Clive Whiley
City of registered office (if applicable)
Country of registered office (if applicable)
4. Details of the shareholder
Full name of shareholder(s) if different from the person(s) subject to the notification obligation, above

City of registered office (if applicable)

Country of registered office (if applicable)

5. Date on which the threshold was crossed or reached
25-Sep-2026
6. Date on which Issuer notified
25-Sep-2026
7. Total positions of person(s) subject to the notification obligation

.	% of voting rights attached to shares (total of 8.A)	% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)	Total of both in % (8.A + 8.B)	Total number of voting rights held in issuer
Resulting situation on the date on which threshold was crossed or reached	11.3476	0.000000	11.3476	65000000
Position of previous notification (if applicable)	8.8678	0.000000	8.8678	50000000

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached
8A. Voting rights attached to shares

Class/Type of shares ISIN code(if possible)	Number of direct voting rights (DTR5.1)	Number of indirect voting rights (DTR5.2.1)	% of direct voting rights (DTR5.1)	% of indirect voting rights (DTR5.2.1)
GB0009067447	65000000	0	11.3476	0.000000
Sub Total 8.A	65000000		11.3476%

8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

Type of financial instrument	Expiration date	Exercise/conversion period	Number of voting rights that may be acquired if the instrument is exercised/converted	% of voting rights
Sub Total 8.B1

8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))

Type of financial instrument	Expiration date	Exercise/conversion period	Physical or cash settlement	Number of voting rights	% of voting rights
Sub Total 8.B2

9. Information in relation to the person subject to the notification obligation
1. Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.

Ultimate controlling person	Name of controlled undertaking	% of voting rights if it equals or is higher than the notifiable threshold	% of voting rights through financial instruments if it equals or is higher than the notifiable threshold	Total of both if it equals or is higher than the notifiable threshold

10. In case of proxy voting
Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional Information

12. Date of Completion
25-Sep-2026
13. Place Of Completion
UK

Additional 10-Year Term adds ~$5.2 Billion of Contracted Revenue at Barber Lake

NEW YORK, Sept. 25, 2026 (GLOBE NEWSWIRE) — Cipher Digital Inc. (NASDAQ: CIFR) (“Cipher” or the “Company”), a leading developer, owner, and operator of industrial-scale data centers, today announced a series of agreements that extend the contracted lease duration of its Barber Lake data center in Colorado City, Texas from 10 years to 20 years and increase total contracted revenue at the facility from $3.8 billion to over $9 billion.

Cipher has executed an amendment to its existing lease with Fluidstack (the “Barber Lake Lease”) that is coupled with a binding commitment with a leading AI lab to lease the facility for an additional 10-year term following the conclusion of the Barber Lake Lease. The additional 10-year commitment with the leading AI lab, which will be governed by a separate lease containing economic terms substantially consistent with the Barber Lake Lease, is expected to generate approximately $5.2 billion of incremental contracted revenue.

In connection with change orders and the continued evolution of tenant requirements at Barber Lake, the lease amendment establishes a phased delivery schedule for the site, with individual data halls expected to be delivered from the fourth quarter of 2026 through the first quarter of 2027. Rent will commence for each data hall as it is delivered, with the first rent commencement expected in the fourth quarter of 2026. Cipher remains on track with the revised delivery schedule.

In connection with the amendment and the change orders, the Company, Fluidstack and the leading AI lab established a cost reimbursement framework, pursuant to which the Company will bear the first $359.3 million of costs in excess of the initial budgeted amount under the Barber Lake Lease. The tenant will reimburse the Company over the aggregate twenty-year term for 50% of any such costs above that amount, payable as additional rent and calculated in a manner to provide Cipher with a contracted rate of return on such reimbursed amounts.

“Extending Barber Lake’s contracted life from 10 to 20 years and adding approximately $5.2 billion of contracted revenue reflects the enduring value of the infrastructure we’re building,” said Tyler Page, Chief Executive Officer. “Barber Lake was designed as a long-lived, mission-critical asset, and securing a firm commitment that extends well beyond the original lease term demonstrates the long-term utility and strategic relevance of the campus. We believe this transaction underscores the quality and enduring strength of our sites, as well as the durability of demand for hyperscale computing capacity.”

About Cipher

Cipher develops and operates industrial-scale data centers engineered for next-generation computing at the highest standards of innovation, precision, and excellence. The Company brings together deep expertise across power sourcing, construction, engineering, operations, real estate, and technology to deliver high-quality data centers purpose built for HPC workloads. By partnering with premier tenants, Cipher seeks to meet the growing demand for industrial-scale data center capacity and become a leading HPC development platform that is built for hyperscale. To learn more about Cipher, please visit https://www.cipherdigital.com/.

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of the federal securities laws of the United States. The Company intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 and includes this statement for purposes of complying with these safe harbor provisions. Any statements made in this press release that are not statements of historical fact, such as statements about the Company’s beliefs and expectations regarding its planned business model and strategy, timing and likelihood of success, capacity, functionality and operation of its data centers, expectations regarding its data center development and operations, potential strategic initiatives, and management plans and objectives, are forward-looking statements and should be evaluated as such. These forward-looking statements generally are identified by the words “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “could,” “seeks,” “intends,” “targets,” “projects,” “contemplates,” “believes,” “estimates,” “strategy,” “future,” “forecasts,” “opportunity,” “predicts,” “potential,” “would,” “will likely result,” “continue,” and similar expressions (including the negative versions of such words or expressions).

These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Cipher and its management, are inherently uncertain. Such forward-looking statements are subject to risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: volatility in the price of Cipher’s securities due to a variety of factors, including changes in the competitive and regulated industry in which Cipher operates, Cipher’s evolving business model and strategy and efforts it may make to modify aspects of its business model or engage in various strategic initiatives, variations in performance across competitors, changes in laws and regulations affecting Cipher’s business, the ability of Cipher’s customers, tenants, and other counterparties to perform their contractual obligations, the ability to Cipher to complete its data centers and future strategic growth initiatives in a timely manner or within anticipated cost estimates, risks relating to the development, construction, and operation of Cipher’s data centers, the availability of capital and financing on acceptable terms, changes in market demand, and the ability to implement business plans, forecasts, and other expectations and to identify and realize additional opportunities. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of Cipher’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025 filed with the Securities and Exchange Commission (“SEC”) on February 24, 2026, Cipher’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2026 filed with the SEC on August 4, 2026, and in Cipher’s subsequent filings with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Cipher assumes no obligation and, except as required by law, does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.

Website Disclosure

The Company maintains a dedicated investor website at https://investors.cipherdigital.com/ (“Investors’ Website”). Financial and other important information regarding the Company is routinely posted on and accessible through the Investors’ Website. Cipher uses its Investors’ Website as a distribution channel of material information about the Company, including through press releases, investor presentations, reports and notices of upcoming events. Cipher intends to utilize its Investors’ Website as a channel of distribution to reach public investors and as a means of disclosing material non-public information for complying with disclosure obligations under Regulation FD. In addition, you may sign up to automatically receive email alerts and other information about the Company by visiting the “Email Alerts” option under the Investor Resources section of Cipher’s Investors’ Website and submitting your email address.

Contacts:

Investor Contact:
Courtney Knight
Head of Investor Relations at Cipher Digital
courtney.knight@cipherdigital.com

Media Contact:
Ryan Dicovitsky
Dukas Linden Public Relations
CipherDigital@DLPR.com

– Partnership will introduce NeuroSigma’s second-generation Monarch eTNS^® System to Firefly’s nationwide network of Evoke™ clinicians –

– Collaboration brings together an FDA-cleared pediatric ADHD treatment and Firefly’s objective brain-function assessment platform and AI-driven ADHD biomarker research –

– Monarch offers an at-home, non-medication treatment option for eligible children ages 7 through 12 ––

KENMORE, N.Y. and LOS ANGELES, Sept. 25, 2026 (GLOBE NEWSWIRE) — Firefly Neuroscience, Inc. (“Firefly”) (NASDAQ: AIFF), an artificial intelligence (“AI”) company advancing precision neuroscience, and NeuroSigma, Inc. (“NeuroSigma”), a bioelectronic medical device company, today announced a strategic partnership to expand clinician awareness of and access to NeuroSigma’s Monarch eTNS^® System through Firefly’s growing nationwide network of Evoke™ clinician customers.

The Monarch eTNS^® System is the first non-drug treatment for pediatric attention-deficit/hyperactivity disorder (“ADHD”) cleared by the U.S. Food and Drug Administration (“FDA”). Under the partnership, Firefly will introduce the Monarch device to psychiatry, neurology and behavioral health practices that use its FDA 510(k)-cleared, AI-powered Evoke™ EEG/ERP platform.

The collaboration brings together complementary technologies designed to address two significant needs in pediatric ADHD care: access to objective information about brain function and availability of a non-medication treatment option for eligible patients.

According to a 2024 study published in the Journal of Clinical Child & Adolescent Psychology, approximately one in nine U.S. children has received an ADHD diagnosis, representing an estimated 7.1 million children. And among the approximately 6.5 million children with current ADHD, nearly one-third received no ADHD-specific treatment.¹ At the same time, many families are seeking alternatives to stimulant medication for their children.²^, ³

“This partnership represents an important step toward a more objective and personalized approach to pediatric ADHD care,” said Greg Lipschitz, Chief Executive Officer of Firefly. “Clinicians need better tools to understand how an individual patient’s brain is functioning, more treatment options from which to choose and objective ways to evaluate changes over time. By introducing NeuroSigma’s FDA-cleared, non-drug therapy to our Evoke clinician network, we are connecting measurement-driven practices with an important treatment option for eligible children and their families.”

Firefly’s Evoke™ platform combines quantitative electroencephalography (“qEEG”) and event-related potential (“ERP”) testing with AI-powered analytics. Drawing upon Firefly’s proprietary database of more than 200,000 EEG/ERP brain scans, Evoke™ provides clinicians with objective information about individual brain function, including in patients whose symptoms may overlap across multiple conditions, and enables clinicians to track changes over time.

In March 2026, Firefly announced the discovery of EEG/ERP biomarkers, identified using data collected through Evoke™, that may help differentiate among the three ADHD presentations: predominantly inattentive, predominantly hyperactive-impulsive and combined. Subject to further research and validation, Firefly believes these findings could ultimately help clinicians better match patients with appropriate treatment approaches and objectively monitor their response to intervention.

The prescription-only Monarch eTNS^® System is a palm-sized device that delivers mild external trigeminal nerve stimulation (eTNS) through a small adhesive patch placed on a child’s forehead while the child sleeps. It is FDA-cleared as a monotherapy for children ages 7 through 12 with ADHD who are not currently taking prescription ADHD medication.

NeuroSigma commenced U.S. sales of its second-generation Monarch device in July 2026, following the development of a waitlist comprising more than 1,500 patients, caregivers and healthcare providers. In September, the company expanded payment options for families, including third-party installment plans.

“For too long, we have relied on symptom checklists and traditional evaluations alone to understand a child’s brain,” said Lauren Hernandez, M.D., a board-certified pediatrician with advanced certification in genomic medicine, and Chief Medical Officer of the pediatric program for NuWell Medicine. “Advanced qEEG technology, such as Evoke™, allows us to see how a child’s brain is actually functioning in real time, giving us a deeper understanding of attention, learning, emotional regulation, and overall neurological health. This technology helps identify the unique patterns behind challenges often labeled as ADHD, while also revealing when symptoms may be driven by anxiety, sensory processing differences, autonomic nervous system dysregulation, or other underlying factors. By understanding how the brain, gut, and autonomic nervous system work together, we can create more personalized and effective roadmaps that support resilience, health, and lifelong success. Evoke™ provides valuable insights that can help validate the need for medication when appropriate, while also helping families avoid unnecessary treatment when the root cause lies elsewhere. We are also excited about emerging tools, such as the Monarch eTNS^® System, which offer new opportunities to support children with ADHD and autism. For the first time, we have objective tools to measure progress and improvement over time, aligning perfectly with the Reformative Medicine approach of identifying what’s off balance, optimizing function, and restoring balance across the body’s interconnected systems.”

Under the agreement, Firefly will introduce the Monarch eTNS^® System to its Evoke™ clinician customers and support clinician education regarding the therapy. NeuroSigma will provide clinical training, prescribing support and product fulfillment through its specialty pharmacy partner.

“Firefly has built a network of clinicians who are already embracing a more objective, measurement-driven approach to brain health,” said Colin Kealey, M.D., President and Chief Executive Officer of NeuroSigma. “These clinics are well positioned to evaluate innovative treatment options for children and families seeking an alternative to medication. With our second-generation Monarch device now shipping and expanded payment options available, this partnership gives us an efficient pathway to educate more clinicians and broaden access to the first FDA-cleared, non-drug treatment for pediatric ADHD.”

Sources

¹ Danielson ML, Claussen AH, Bitsko RH, Katz SM, Newsome K, Blumberg SJ, Kogan MD, Ghandour R. ADHD Prevalence Among U.S. Children and Adolescents in 2022: Diagnosis, Severity, Co-Occurring Disorders, and Treatment. J Clin Child Adolesc Psychol. 2024 May-Jun;53(3):343-360. doi: 10.1080/15374416.2024.2335625. Epub 2024 May 22. PMID: 38778436; PMCID: PMC11334226.

² Lu SV, Leung BMY, Bruton AM, Millington E, Alexander E, Camden K, Hatsu I, Johnstone JM, Arnold LE. Parents’ priorities and preferences for treatment of children with ADHD: Qualitative inquiry in the MADDY study. Child Care Health Dev. 2022 Sep;48(5):852-861. doi: 10.1111/cch.12995. Epub 2022 Mar 25. PMID: 35244227; PMCID: PMC10215012.

³ Drechsler R, Brem S, Brandeis D, Grünblatt E, Berger G, Walitza S. ADHD: Current Concepts and Treatments in Children and Adolescents. Neuropediatrics. 2020 Oct;51(5):315-335. doi: 10.1055/s-0040-1701658. Epub 2020 Jun 19. PMID: 32559806; PMCID: PMC7508636.

About NeuroSigma

NeuroSigma is a bioelectronic medical device company based in Los Angeles, California. Its lead product, the Monarch eTNS^® System, is the first non-drug treatment for pediatric ADHD cleared by the FDA. NeuroSigma is also investigating the Monarch eTNS^® System in additional neurodevelopmental and neurological indications, including autism spectrum disorder, learning disabilities and drug-resistant epilepsy, for which the FDA has granted Breakthrough Device Designation; these pipeline indications are investigational and not FDA-cleared.

For more information, visit www.neurosigma.com and www.monarch-etns.com.

About Firefly Neuroscience

Firefly Neuroscience, Inc. (NASDAQ: AIFF) is an Artificial Intelligence (“AI”) company advancing precision neuroscience, applying AI and large-scale electrophysiological data to give clinicians a more complete, objective picture of how an individual patient’s brain is functioning. Firefly’s proprietary database consists of over 200,000 EEG/ERP brain scans, which the Company believes to be the world’s largest known standardized EEG/ERP repository. Firefly’s EEG-based, AI-driven, and FDA-510(k)-cleared Evoke™ System is designed to support diagnostic and treatment monitoring methods for conditions such as depression, dementia, anxiety disorders, concussions, ADHD, and PTSD.

Please visit www.fireflyneuro.com for more information.

Forward-Looking Statements

Certain statements in this press release may constitute “forward-looking statements” for purposes of the federal securities laws concerning Firefly, including statements regarding the anticipated benefits, scope, and results of the collaboration between Firefly and NeruSigma, statements regarding NeruSigma’s business, business, product and commercial plans; Firefly’s ADHD biomarker research and product development; and statements relating to Firefly’s management team’s expectations, hopes, beliefs, intentions, or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting Firefly will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond Firefly’s control) and other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those factors described under the heading “Risk Factors” in the reports and other filings of Firefly with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should any of Firefly’s assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. It is not possible to predict or identify all such risks. Forward-looking statements included in this press release only speak as of the date they are made, and Firefly does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

Important Safety Information

The Monarch eTNS^® System is available by prescription only. It is indicated for the treatment of pediatric ADHD as a monotherapy for patients ages 7 through 12 who are not currently taking prescription ADHD medication and is intended for home use during sleep under the supervision of a caregiver. Monarch should not be used by patients with an implanted cardiac or neurostimulation system or an implanted metallic or electronic device in the head. Do not apply the device to the neck or chest, do not use it in the bath or shower, and do not use it in the presence of electrical monitoring equipment such as cardiac monitors. Apply the patch only to healthy, clean, intact skin. The most commonly reported side effects are drowsiness, increased appetite, trouble sleeping, teeth clenching, headache, and fatigue. Talk with your child’s clinician about whether Monarch is right for your child.

For complete safety information, see the Instructions for Use.

Investor & Media Contacts

For Firefly
Stephen Kilmer
(646) 274-3580
stephen.kilmer@fireflyneuro.com

For NeuroSigma
Colin Kealey, M.D.
President and Chief Executive Officer
ckealey@neurosigma.com